Business Description
Bone Biologics Corp
NAICS : 541714
SIC : 2836
ISIN : US0980706008
Total Employee Number:
2Description
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.94 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 81.8 | |||||
3-Year EPS without NRI Growth Rate | 83.1 | |||||
3-Year FCF Growth Rate | 82.7 | |||||
3-Year Book Growth Rate | -82.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 8.5 | |||||
9-Day RSI | 20.18 | |||||
14-Day RSI | 28.53 | |||||
3-1 Month Momentum % | -0.74 | |||||
6-1 Month Momentum % | -21.97 | |||||
12-1 Month Momentum % | -55.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.11 | |||||
Quick Ratio | 16.11 | |||||
Cash Ratio | 14.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -446.5 | |||||
Shareholder Yield % | -226.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -55.9 | |||||
ROA % | -52.38 | |||||
ROIC % | -4238.7 | |||||
3-Year ROIIC % | -17.92 | |||||
ROC (Joel Greenblatt) % | -2736.47 | |||||
ROCE % | -58.68 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.41 | |||||
Price-to-Tangible-Book | 0.41 | |||||
EV-to-EBIT | 0.87 | |||||
EV-to-EBITDA | 0.87 | |||||
EV-to-FCF | 1.02 | |||||
| Price-to-Net-Current-Asset-Value | 0.41 | |||||
| Price-to-Net-Cash | 0.46 | |||||
Earnings Yield (Greenblatt) % | 114.94 | |||||
FCF Yield % | -133.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BBLG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bone Biologics Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.511 | ||
| Beta | 1.5798 | ||
| 3-Year Sharpe Ratio | -0.92 | ||
| 3-Year Sortino Ratio | -1.22 | ||
| Volatility % | 71.51 | ||
| 14-Day RSI | 28.53 | ||
| 14-Day ATR ($) | 0.086883 | ||
| 20-Day SMA ($) | 1.282 | ||
| 12-1 Month Momentum % | -55.45 | ||
| 52-Week Range ($) | 1.05 - 4.1299 | ||
| Shares Outstanding (Mil) | 1.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bone Biologics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bone Biologics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 111 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 20 days | ||
| General meeting for 2026 | 2026-08-11 11:00 | In 18 days | ||
| First quarter earnings results for 2026 | 2026-05-14 | 1.30 (-3.09%) | ||
| Annual report for 2025 | 2026-03-02 | 1.15 (-1.12%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.70 (-3.95%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 | 2.31 (-19.51%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 2.35 (+0.21%) | ||
| 0.166667:1 Stock Split | 2025-06-10 | 4.52 (-5.89%) | ||
| General meeting for 2025 | 2025-05-30 11:00 | 5.10 (+3.62%) |
Show
Entries
Bone Biologics Corp Frequently Asked Questions
What is Bone Biologics Corp(BBLG)'s stock price today?
The current price of BBLG is $1.07. The 52 week high of BBLG is $4.13 and 52 week low is $1.05.
When is next earnings date of Bone Biologics Corp(BBLG)?
The next earnings date of Bone Biologics Corp(BBLG) is 2026-08-14 Est..
Does Bone Biologics Corp(BBLG) pay dividends? If so, how much?
Bone Biologics Corp(BBLG) does not pay dividend.
Guru Commentaries on NAS:BBLG
No articles.
Press Release
Articles on Bone Biologics Corp
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers